| Dr Marina Boruk, MD | |
|
450 Clarkson Ave Ste H, Brooklyn, NY 11203-2012 | |
| (718) 270-1638 | |
| Not Available |
| Full Name | Dr Marina Boruk |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Experience | 23 Years |
| Location | 450 Clarkson Ave Ste H, Brooklyn, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235166281 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kings County Hospital Center | Brooklyn, NY | Hospital |
| Suny/downstate University Hospital Of Brooklyn | Brooklyn, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Physicians Of Brooklyn, Inc. | 0749192284 | 162 |
News Archive
NovaQuest Capital Management, L.L.C. is pleased to announce the final closing of NovaQuest Pharma Opportunities Fund III, L.P., a $459 million private equity fund focused on providing structured finance solutions to biopharmaceutical companies ("Fund III").
Vitamin A deficiency has been associated with the development of lung cancer in laboratory studies. However, clinical trials of natural and synthetic derivatives of vitamin A, called retinoids, for the prevention of lung cancer have been largely unsuccessful in the general population.
Survey published to coincide with International Clinical Trials Day shows NHS needs to do more to create a research culture.
Ductal carcinoma in situ (DCIS) is considered a precursor lesion for invasive breast cancer if untreated, and is found in approximately 45% of patients with invasive ductal carcinoma (IDC). Patients with DCIS only (not accompanied by invasive disease) have a 5-year-survival of nearly 100%, compared to 89% for all stages of invasive breast cancer (24% for patients with distant metastasis).
› Verified 2 days ago
| Entity Name | University Physicians Of Brooklyn, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366506271 PECOS PAC ID: 0749192284 Enrollment ID: O20040401000120 |
News Archive
NovaQuest Capital Management, L.L.C. is pleased to announce the final closing of NovaQuest Pharma Opportunities Fund III, L.P., a $459 million private equity fund focused on providing structured finance solutions to biopharmaceutical companies ("Fund III").
Vitamin A deficiency has been associated with the development of lung cancer in laboratory studies. However, clinical trials of natural and synthetic derivatives of vitamin A, called retinoids, for the prevention of lung cancer have been largely unsuccessful in the general population.
Survey published to coincide with International Clinical Trials Day shows NHS needs to do more to create a research culture.
Ductal carcinoma in situ (DCIS) is considered a precursor lesion for invasive breast cancer if untreated, and is found in approximately 45% of patients with invasive ductal carcinoma (IDC). Patients with DCIS only (not accompanied by invasive disease) have a 5-year-survival of nearly 100%, compared to 89% for all stages of invasive breast cancer (24% for patients with distant metastasis).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Marina Boruk, MD 22 N 6th St Apt 23gh, Brooklyn, NY 11249-3093 Ph: (646) 481-1311 | Dr Marina Boruk, MD 450 Clarkson Ave Ste H, Brooklyn, NY 11203-2012 Ph: (718) 270-1638 |
News Archive
NovaQuest Capital Management, L.L.C. is pleased to announce the final closing of NovaQuest Pharma Opportunities Fund III, L.P., a $459 million private equity fund focused on providing structured finance solutions to biopharmaceutical companies ("Fund III").
Vitamin A deficiency has been associated with the development of lung cancer in laboratory studies. However, clinical trials of natural and synthetic derivatives of vitamin A, called retinoids, for the prevention of lung cancer have been largely unsuccessful in the general population.
Survey published to coincide with International Clinical Trials Day shows NHS needs to do more to create a research culture.
Ductal carcinoma in situ (DCIS) is considered a precursor lesion for invasive breast cancer if untreated, and is found in approximately 45% of patients with invasive ductal carcinoma (IDC). Patients with DCIS only (not accompanied by invasive disease) have a 5-year-survival of nearly 100%, compared to 89% for all stages of invasive breast cancer (24% for patients with distant metastasis).
› Verified 2 days ago
Anthony Paul Vastola, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 300 Cadman Plz W, Suite 1301, Brooklyn, NY 11201 Phone: 929-252-1566 Fax: 718-208-4663 | |
Harry Pantelides, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 170 Broadway, Brooklyn, NY 11211 Phone: 718-618-9181 | |
Dr. Marc David Gottlieb, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 6740 4th Ave Fl 3, Brooklyn, NY 11220 Phone: 929-455-2700 | |
Dr. Sara Abu Ghanem, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 450 Clarkson Ave # Msc126, Brooklyn, NY 11203 Phone: 718-270-1638 Fax: 718-270-3924 | |
Dr. Mayer Adler, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 6910 Bay Parkway, Brooklyn, NY 11204 Phone: 718-236-3900 Fax: 718-236-8787 | |
Dr. Ofer Azoulay, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 185 Montague St Fl 5, Brooklyn, NY 11201 Phone: 929-284-6120 | |
Simon H Friedman, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1636 East 14th Str, Suite 120, Brooklyn, NY 11229 Phone: 718-339-2300 Fax: 718-998-8020 |